Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efruxifermin (Primary)
Indications Non-alcoholic steatohepatitis
Focus Therapeutic Use
Acronyms SYMMETRY
Sponsors Akero Therapeutics

Most Recent Events

09 May 2025 According to a Akero Therapeutics media release, company announced publication of results from the Phase 2b SYMMETRY trial in the New England Journal of Medicine.
09 May 2025 Results presented in the Akero Therapeutics media release.
09 May 2025 Results presented in the Akero Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com